Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMI/REL vs PIP/TAZ for HABP/VABP (China)
CTR20180461Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of imipenem + cilastatin + relebactam in hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), sponsored by Merck & Co.. Started May 2018; status: completed.
02
Drugs
imipenem + cilastatin + relebactam
03
Conditions
hospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on CTR20180461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180461.